ArticlePediatric cardiology2026
Intrapericardial Triamcinolone Instillation for Recurrent Pericardial Effusion in Pediatric Patients: A Review of Efficacy and Safety.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrapericardial administration of the glucocorticoid medication triamcinolone is reported useful in the treatment of recurrent pericardial effusion in adult patients. Nevertheless, the studies on triamcinolone use in pediatric patients are scarce, and the effectiveness and side effect profile of intrapericardial triamcinolone in children is not well characterized. This single center retrospective case series seeks to expand on the efficacy, side effects, and safety of intrapericardial triamcinolone in pediatric patients suffering from recurrent idiopathic pericardial effusions. Nine pediatric patients who received intrapericardial triamcinolone for recurrent idiopathic pericardial effusion at a single center from 2015 to 2025 were included. The pericardial effusion progression was observed with serial echocardiograms and new symptoms appeared after triamcinolone administration. Five patients demonstrated resolution of pericardial effusion, three had improvement, and one relapsed after intrapericardial triamcinolone administration. Five patients suffered from short-term steroid-like side effects that resolved prior to discharge, and two died of underlying disease rather than treatment with triamcinolone. These findings are consistent with the idea that intrapericardial triamcinolone can be utilized as a safe and effective adjunctive treatment option in children with recurrent idiopathic pericardial effusion.
Indexed as
Identifiers
42203961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.